SetPoint Medical Corp: Business Overview, Financials & Competitive Analysis
SetPoint Medical Corp scores 8/10 on the AskCyborg Cyborg Score (Strong). FDA-approved first-in-class bioelectronic neuroimmune modulation device with established clinical efficacy in RA and expedited pathway for multiple sclerosis expansion. SetPoint Medical has received FDA approval for its first-in-class SetPoint System, a transformative milestone establishing commercial viability. The company has raised $581M and holds a strong platform expansion strategy with.
What is SetPoint Medical Corp's industry? SetPoint Medical Corp (setpointmedical.com) operates in Neurostimulation Devices. AskCyborg classifies SetPoint Medical Corp under Neurostimulation Devices in its company registry.
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with autoimmune diseases through a novel platform designed to stimulate the vagus nerve to activate innate anti-inf...
Cyborg Score thesis
FDA-approved first-in-class bioelectronic neuroimmune modulation device with established clinical efficacy in RA and expedited...
Read the full analyst-debate transcript →Get the Latest SetPoint Medical Corp Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSetPoint Medical Corp Overview
Pro stress-test →SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with autoimmune diseases through a novel platform designed to stimulate the vagus nerve to activate innate anti-inflammatory pathways to produce a systemic immune-restorative effect. The company achieved a major milestone in July 2025 when the U.S. Food and Drug Administration (FDA) approved the company's SetPoint System, a breakthrough innovation for people with rheumatoid arthritis (RA).
Strategic Profile
Pro stress-test →The SetPoint System is the first neuroimmune modulation therapy available for people living with rheumatoid arthritis (RA), offering a novel, device-based alternative for those who do not respond to or cannot tolerate biologic or targeted drug therapies. In March 2024, SetPoint received breakthrough device designation from the FDA for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS). The company is expanding its addressable market beyond RA into other chronic autoimmune conditions.
Competitive Landscape
Pro stress-test →Competitors include Salvia BioElectronics, Mainstay Medical, Saluda Medical, Aleva Neurotherapeutics, and Curonix. SetPoint differentiates through its first-in-class FDA approval for neuroimmune modulation addressing a significant unmet need in RA treatment, where only 25% of RA patients are satisfied with their therapy and up to 50% discontinue their prescribed therapies within two years. The company's platform approach allows potential expansion into multiple autoimmune conditions.
Industry Context
SetPoint Medical Corp operates in Neurostimulation Devices.
Key facts
Headquarters: Valencia, CA, US · Employees: 90